0.007 µM, which is equal to the IC 50 value of trovirdine. Notably, HI-244 was 20 times more effective than trovirdine against the multidrugresistant HIV-1 strain RT-MDR with a V106A mutation (as well as additional mutations involving the RT residues 74V, 41L and 215Y) and seven times more potent than trovirdine against the NNRTIresistant HIV-1 strain A17 with a Y181C mutation.
Multidrug resistance against antiretroviral agents has emerged as the major challenge to a more successful outcome of contemporary treatment programmes for individuals infected with human immunodeficiency virus type 1 (HIV-1) (Miles, 1997) . Therefore, the development of novel antiviral agents that are effective against multidrugresistant HIV-1 has become a focal point of international AIDS research (Miles, 1997; Vig et al., 1998; Mao et al., 1998; Bell et al., 1995) . Recently, we developed a computer model for the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket of HIV-1 RT as an effective tool for rational structure-based design of potent NNRTIs Sudbeck et al., 1998) . Using this model we synthesized a number of NNRTIs comprising various phenyl thiourea compounds, and detailed structure-activity studies demonstrated the importance of various groups to obtain potent activity . Our modelling studies revealed several details regarding the RT mutations associated with NNRTI resistance: the spacious wing 2 region of the butterfly-shaped NNRTI-binding pocket contains multiple aromatic residues, including Y181 and Y188, which occupy a substantial volume. Y181C, Y188C and Y188H mutations in drug-resistant HIV strains result in a larger unoccupied volume in the binding pocket. Preferred inhibitors should maximize the occupancy in the wing 2 region of the NNRTI-binding site; inhibitors that lack a compatible functional group to interact with the mutated residues and/or a sufficiently large group to provide surface contact with the altered wing 2 region, would not be effective against NNRTI-resistant HIV-1 strains with these mutations (Mao et al., 1999; Bell et al., 1995) .
Materials and Methods: Chemistry
Composite NNRTI binding pocket, docking and K i prediction
The procedure used to construct the composite NNRTIbinding pocket that takes into account information from nine different crystal structures of HIV RT-inhibitor complexes has been described previously .
Synthesis
In the present study, we have synthesized a series of thiourea compounds in which one of the nitrogen atoms of the thiourea is attached to a para substituted phenyl ring through an ethyl bridge and the other nitrogen atom is attached to a 5-bromo substituted pyridyl ring. The title compounds were synthesized as shown in Figure 1 , in which a thiocarbonyl reagent was prepared from substituted phenethylamine or pyridylethylamine and 1,1′-thiocarbonyl-diimidazole in acetonitrile solvent at room temperature for 12 h, and condensed with the appropriate 2-amino compounds in dimethyl formamide (DMF) at 100°C for 15 h (Bell et al., 1995) . After work up, the derivatives were purified by column chromatography. Trovirdine was synthesized according to the literature procedure (Bell et al., 1995) . 3159, 3042, 2931, 2827, 1587, 1510, 1464, 1311, 1225, 1165, 1088, 1034, 820, 773 158.0, 151.9, 145.8, 140.7, 130.6, 128.6, 113.8, 113.7, 112.1, 55.1, 46.9 and 33.8 3213, 3155, 3086, 3028, 2868, 1595, 1560, 1533, 1477, 1336, 1308, 1238, 1211, 1173, 1136, 1092, 1026, 933, 869, 827, 791, 741, 694 
N-[2-(4-bromophenethyl)]-N′-[2-(5-bromopyridyl)]thiourea (HI-243)
Yield: 75%; m.p. 184-185°C; UV: (MeOH) λ max : 207, 257, 276, 306 nm, IR (KBr) ν 3454, 3221, 3153, 3086, 3022, 2929, 1595, 1560, 1531, 1471, 1402, 1338, 1304, 1227, 1169, 1091, 1072, 1013, 820, 708 cm 151.6, 146.3, 141.3, 133.6, 131.6, 130.6, 113.5, 112.9, 46.7 and 34.3 , 3228, 3161, 3086, 2917, 2866, 1595, 1543, 1466, 1307, 1265, 1229, 1188, 1140, 1003, 829, 812, 777 
N-[2-(4-chlorophenethyl)]-N′-[2-(5-bromopyridyl)]thiourea (HI-255)
Yield: 71%; m.p. 180-183°C; UV (MeOH) λ max 206, 209, 219, 256, 275, 305 nm; IR (KBr) ν 3221, 3153, 3086, 3022, 2931 , 1674 , 1593 , 1562 , 1533 , 1473 , 1406 , 1340 , 1304 , 1265 , 1227 , 1169 , 1138 , 1092 , 1016 , 3160, 3083, 3025, 2925, 2861, 1592, 1552, 1529, 1475, 1357, 1311, 1226, 1166, 1091, 1070, 1002, 864, 823, 746, 698, 561 3159, 3089, 3041, 2933, 2870, 1595, 1558, 1533, 1514, 1332, 1306, 1265, 1227, 1186, 1136, 1094, 1007, 910, 862, 827, 708 
Materials and Methods: Virology
Purified RT assays and p24 assays measuring anti-HIV activity
The RT inhibitory activity of the compounds was tested using purified recombinant RT and cell-free Quan-T-RT assay system (Amersham), which utilizes the scintillation proximity assay principle, as previously described in detail Mao et al., 1998) . In the assay, a DNA/RNA template is bound to SPA beads via a biotin/streptavidin linkage. The primer DNA is a 16-mer oligo(T), which has been annealed to a poly(rA) template. The primer-template is bound to a streptavidin-coated SPA bead. 
p24 Assays for anti-HIV activity
The anti-HIV activity of the compounds was measured by determining their ability to inhibit the replication of the NNRTI-sensitive HIV-1 strain HTLV IIIB , multidrugresistant HIV-1 strain RT-MDR, and the NNRTI-resistant RT Y181C mutant HIV-1 strain A17 in peripheral blood mononuclear cells (PBMCs) from healthy volunteer donors, as described previously (Zarling et al., 1990; Uckun et al., 1998; Sudbeck et al., 1998; Mao et al., 1998) . Normal human PBMCs from HIV-negative donors were cultured for 72 h in RPMI-1640 supplemented with 20% (v/v) heat-inactivated foetal bovine serum (FBS), 3% interleukin-2, 2 mM L-glutamine, 25 mM HEPES, 2 g/l NaHCO 3 , 50 µg/ml gentamycin, and 4 µg/ml phytohaemagglutinin prior to exposure to HIV-1 at a multiplicity of infection (m.o.i.) of 0.1 during a 1 h adsorption period at 37°C in a humidified 5% CO 2 atmosphere. Subsequently, cells were cultured in 96-well microtitre plates (100 µl/well; 2×10 6 cells/ml, triplicate wells) in the presence of various inhibitor concentrations, and aliquots of culture supernatants were removed from the wells on the seventh day after infection for p24 antigen enzyme immunoassays (EIA), as previously described (Erice et al., 1993; Zarling et al., 1990; Uckun et al., 1998) . The applied p24 EIA was the unmodified kinetic assay commercially available from Coulter/Immunotech, which utilizes a murine monoclonal antibody to HIV core protein coated onto microwell strips to which the antigen present in the test culture supernatant samples binds. Percentage of inhibition of viral replication was calculated by comparing the p24 values from the test substance-treated infected cells with p24 values from untreated infected cells (virus controls). In parallel, the effects of various treatments on cell viability were also examined, as described previously (Erice et al., 1993; Zarling et al., 1990) . In brief, non-infected normal PBMCs were treated with each compound for 7 days under identical experimental conditions. A microculture tetrazolium assay (MTA), using 2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-5-[(phenylamino)-carbonyl]-2H-t etrazolium hydroxide (XTT), was performed to quantify cellular proliferation.
HIV-1 mutant strains
The following reagents were obtained through the AIDS Research and Reference Reagent Program, AIDS Program (NIAID, National Institutes of Health, Bethesda, Md., USA): nevirapine-resistant HIV-1 (A17, Y181C) from D. Richman (Richman et al., 1991) and HIV-1 RTMDR1 (106A, 74V, 41L and 215Y ) from B Larder (Larder et al., 1993) .
HI-244 inhibition of HIV-1

Results and Discussion
The parent compound HI-275, with an unsubstituted phenyl ring, was slightly less effective than trovirdine and inhibited recombinant RT with an IC 50 value of 1.3 µM. Notably, the para-substitution of the phenyl ring with various functional groups had a major impact on the RTinhibitory function of HI-275. The para-methyl substituted phenyl compound N-[2-(4-methylphenyl) ethyl]-N′-[2-(5-bromopyridyl)]-thiourea (compound HI-244) inhibited recombinant RT better than trovirdine or compound HI-275. None of the remaining compounds were as effective as trovirdine against recombinant RT. The calculated molecular surface values (MS in Table 1) vary from 274 to 302 Å 2 and the buried surface values range from 79 to 84%. However, the trend of the final calculated binding constants, which vary from 0.25 µM for HI-244 to 84 µM for HI-231, has more to do with the LIPO score and hydrophobicity of these compounds, and generally correlated well with the trend of the experimentally determined IC 50 values. As shown in Figure 1 , HI-244 is positioned very favourably within the wing 2 region of the NNRTI-binding pocket, which is reflected by the low calculated binding constant (K i value) for this thiourea compound.
We next evaluated the ability of HI-244 to inhibit HIV-1 replication in human PBMCs. HI-244 effectively inhibited the replication of HIV-1 strain HTLV IIIB in PBMCs with an IC 50 value of 0.007 µM, which is equal to the IC 50 value of trovirdine (Table 1) . Notably, HI-244 was 20 times more effective than trovirdine against the multi-drug-resistant HIV-1 strain RT-MDR with a V106A mutation (as well as additional mutations involving RT residues 74V, 41L and 215Y ) and seven times more potent than trovirdine against the NNRTI-resistant HIV-1 strain A17 with a Y181C mutation. The selectivity index of HI-244 was >10000 against the wild-type HIV-1 strain HTLV IIIB , >71000 against the multidrug-resistant V106A mutant strain RT-MDR and >1000 against the NNRTI-resistant Y181C mutant strain A17. These findings establish the lead para-methyl substituted phenyl thiourea compound HI-244 as an effective NNRTI against drug-sensitive, NNRTI-resistant as well as multidrug-resistant strains of HIV-1.
Clearly, the para-substituted group lies within a hydrophobic region indicated by the composite NNRTIbinding pocket (Figure 2a) , which we constructed previously Vig et al., 1998; Mao et al., 1998) . This region contains the aromatic rings of residues W229 and Y188, which would interact favourably with a *MS, molecular surface area calculated using Connolly's MS programme (Connolly, 1983) . Defined as boundary of volume within any probe sphere (meant to represent a water molecule) of given radius sharing no volume with hard sphere atoms which make up the molecule. Values are slightly smaller than those approximated by Ludi programme. †BS, buried surface: percentage of molecular surface in contact with protein calculated by Ludi based on docked positions. Based on published crystal structures of RT complexes, our calculation shows that these values could be as low as 77% (in RT-HEPT complex) and can be as high as 90% (in RT-APA complex) but most of them average around 84%. ‡Ludi K i values were calculated based on modified empirical score function in the Ludi programme (Bohm, 1992 and Bohm, 1994 hydrophobic group (Figure 2b) . Therefore, the observed inhibition level of the para-substituted compounds against wild-type HIV-1 is generally proportional to the hydrophobicity of the para-substituted group (Table 1) . The potency of the para-substituted compounds is consistent with the following trend: hydrophobic group>polar group>hydrophilic group. The para-methyl group on the HI-244 compound is predicted to reside closer to the Y181 residue (C to Cα distance 5.5 Å) than to the V106 residue (C to Cα distance 8.1 Å). Therefore, the Y181 mutation was anticipated to reduce the potency of a parasubstituted compound more than the V106 mutation. This prediction was experimentally confirmed by showing that the Y181C mutant strain (A17 strain) exhibits a 10-fold resistance to HI-244 whereas the V106A mutant strain (RT-MDR) shows no resistance. The apparent van der Waals contact between the compound and Y181 after its mutation to a smaller cysteine residue may help explain the observed resistance. However, we are not certain about the reason for the demonstrated superior activity of HI-244 against the V106A RT mutant relative to the wild-type RT. We speculate that the V106A mutation may enable the compound to reposition itself in the binding site, leading to improved contacts between the para-methyl group and Y188 resulting in a better binding affinity (Figure 2b ). In contrast, trovirdine would not benefit from such a mutation owing to the absence of a para-methyl group (trovirdine is 20-times less potent than HI-244 against the RT-MDR strain). The presence of a para-methyl group in HI-244 contributes to an increase (relative to trovirdine) in the molecular volume in the wing 2 region of the binding site by 18 Å 3 . In the NNRTI-resistant A17 strain (Y181C mutation), the wing 2 region of the mutant RT becomes larger when Y181 is mutated to a smaller cysteine residue, as observed in the crystal structure of the Y181C mutant RT protein (Das et al., 1996) . These results, showing a sevenfold higher potency of HI-244 relative to trovirdine, are consistent with our previously reported hypothesis that an NNRTI compound containing larger (and compatible) functional groups at the wing 2 region of the binding site can provide better inhibitory activity against these HIV RT mutants (Mao et al., 1999) . Nitrogen is coloured in blue, bromine in brown, sulphur in yellow, carbon in gray and other hydrogens in white. The residues in contact with the compound are labelled and are shown in stick model (pink for sidechains and steel-blue for mainchains), prepared using INSIGHTII (1996) . (b) Composite binding pocket of the NNRTI binding site of HIV-1 RT is illustrated as grid lines representing the collective van der Waals surface. The surface model was constructed as previously described Mao et al., 1998; Sudbeck et al., 1998) . The stick model of the docked compound HI-244 in the composite NNRTI binding pocket is also depicted. Blue represents the hydrophobic region, red hydrogenbond region and yellow polar region. The methyl group is compatible with the hydrophobic region at Wing 2 region.
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